Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) con...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
1979
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009890/ |
| id |
pubmed-2009890 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-20098902009-09-10 Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Nicholson, R. I. Maynard, P. V. Research Article Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) content. Twice daily i.m. injections of either 5 micrograms or 0.5 micrograms ICI 118630 in saline were as effective as ovariectomy or tamoxifen therapy in causing the regression of ER+ DMBA-induced mammary tumours. ER- mammary tumours showed a more equivocal overall response to ICI 118630, some tumours progressing, others regressing. About one-third of the ER+ tumours disappeared in the 20-day treatment period. Those tumours which did regrow after the cessation of treatment proved to be hormone-dependent. In addition to the inhibitory effects of the LH-RH agonist on pre-existing tumours, ICI 118630 also reduced the total number of new tumours formed during and after treatment. 1979-03 /pmc/articles/PMC2009890/ /pubmed/380618 Text en |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Nicholson, R. I. Maynard, P. V. |
| spellingShingle |
Nicholson, R. I. Maynard, P. V. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| author_facet |
Nicholson, R. I. Maynard, P. V. |
| author_sort |
Nicholson, R. I. |
| title |
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| title_short |
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| title_full |
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| title_fullStr |
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| title_full_unstemmed |
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| title_sort |
anti-tumour activity of ici 118630, a new potent luteinizing hormone-releasing hormone agonist. |
| description |
Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) content. Twice daily i.m. injections of either 5 micrograms or 0.5 micrograms ICI 118630 in saline were as effective as ovariectomy or tamoxifen therapy in causing the regression of ER+ DMBA-induced mammary tumours. ER- mammary tumours showed a more equivocal overall response to ICI 118630, some tumours progressing, others regressing. About one-third of the ER+ tumours disappeared in the 20-day treatment period. Those tumours which did regrow after the cessation of treatment proved to be hormone-dependent. In addition to the inhibitory effects of the LH-RH agonist on pre-existing tumours, ICI 118630 also reduced the total number of new tumours formed during and after treatment. |
| publishDate |
1979 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009890/ |
| _version_ |
1611403304766537728 |